212 related articles for article (PubMed ID: 28943101)
21. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.
Chi HC; Chen SL; Cheng YH; Lin TK; Tsai CY; Tsai MM; Lin YH; Huang YH; Lin KH
Cell Death Dis; 2016 Aug; 7(8):e2324. PubMed ID: 27490929
[TBL] [Abstract][Full Text] [Related]
22. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
23. Retinoic acid-induced tissue transglutaminase and apoptosis in vascular smooth muscle cells.
Ou H; Haendeler J; Aebly MR; Kelly LA; Cholewa BC; Koike G; Kwitek-Black A; Jacob HJ; Berk BC; Miano JM
Circ Res; 2000 Nov; 87(10):881-7. PubMed ID: 11073883
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
25. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
26. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
[TBL] [Abstract][Full Text] [Related]
27. Protective effects of hepatic stellate cells against cisplatin-induced apoptosis in human hepatoma G2 cells.
Zhang L; Li Y; Qiao L; Zhao Y; Wei Y; Li Y
Int J Oncol; 2015 Aug; 47(2):632-40. PubMed ID: 26035065
[TBL] [Abstract][Full Text] [Related]
28. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas.
Lee J
Arch Pharm Res; 2010 Sep; 33(9):1401-9. PubMed ID: 20945139
[TBL] [Abstract][Full Text] [Related]
29. [Effects of over-expressed Smac gene coupling with cisplatin on proliferation and apoptosis of hepatocarcinoma cells].
Guo CX; Li YB; DU HY; Liu Y; Sun L; Jin MH; Sun ZW
Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):674-7. PubMed ID: 18822208
[TBL] [Abstract][Full Text] [Related]
30. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells.
Zhao JL; Zhao J; Jiao HJ
Appl Biochem Biotechnol; 2014 Jan; 172(2):784-91. PubMed ID: 24122665
[TBL] [Abstract][Full Text] [Related]
31. Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis.
Liu FY; Wu YH; Zhou SJ; Deng YL; Zhang ZY; Zhang EL; Huang ZY
Oncol Rep; 2014 Aug; 32(2):835-44. PubMed ID: 24919588
[TBL] [Abstract][Full Text] [Related]
32. Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.
Monteagudo A; Ji C; Akbar A; Keillor JW; Johnson GVW
Biochem Biophys Res Commun; 2017 Jan; 482(4):942-947. PubMed ID: 27899316
[TBL] [Abstract][Full Text] [Related]
33. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
34. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells.
Huaying S; Dong Y; Chihong Z; Xiaoqian Q; Danying W; Jianguo F
Med Sci Monit; 2016 Dec; 22():5041-5048. PubMed ID: 28002389
[TBL] [Abstract][Full Text] [Related]
35. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
37. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
38. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
39. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
40. Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
Jung HJ; Han EH; Jang IK; Yoon SH; Park JE
Anticancer Res; 2019 Nov; 39(11):6165-6173. PubMed ID: 31704844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
